GILD Gilead Sciences Inc
Price (delayed)
$105.23
Market cap
$131.05B
P/E Ratio
276.92
Dividend/share
$3.1
EPS
$0.38
Enterprise value
$147.77B
Gilead Sciences, Inc. /ˈɡɪliəd/, is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the
Highlights
The quick ratio has grown by 46% from the previous quarter and by 13% YoY
GILD's gross profit is up by 9% YoY and by 4.5% QoQ
GILD's P/E is 102% above its 5-year quarterly average of 135.9 but 18% below its last 4 quarters average of 336.3
Gilead Sciences's equity has decreased by 15% YoY but it has increased by 4.6% from the previous quarter
GILD's EPS has dropped by 92% year-on-year
The company's net income has shrunk by 92% YoY
Key stats
What are the main financial stats of GILD
Market
Valuations
Earnings
Shares outstanding
1.25B
Market cap
$131.05B
Enterprise value
$147.77B
Price to earnings (P/E)
276.92
Price to book (P/B)
6.78
Price to sales (P/S)
4.56
EV/EBIT
88.59
EV/EBITDA
33.32
EV/Sales
5.14
Revenue
$28.75B
Gross profit
$22.5B
Operating income
$1.66B
Net income
$480M
EBIT
$1.67B
EBITDA
$4.44B
Free cash flow
$10.31B
Per share
Balance sheet
Liquidity
EPS
$0.38
EPS diluted
$0.38
Free cash flow per share
$8.26
Book value per share
$15.51
Revenue per share
$23.06
TBVPS
$24.65
Total assets
$59B
Total liabilities
$39.75B
Debt
$26.71B
Equity
$19.33B
Working capital
$7.17B
Debt to equity
1.38
Current ratio
1.6
Quick ratio
1.2
Net debt/EBITDA
3.77
Margins
Efficiency
Dividend
EBITDA margin
15.4%
Gross margin
78.3%
Net margin
1.7%
Operating margin
5.8%
Return on assets
0.9%
Return on equity
2.6%
Return on invested capital
5.1%
Return on capital employed
3.5%
Return on sales
5.8%
Dividend yield
2.95%
DPS
$3.1
Payout ratio
815.8%
GILD stock price
How has the Gilead Sciences stock price performed over time
Intraday
0.86%
1 week
-0.43%
1 month
-1.73%
1 year
57.18%
YTD
13.92%
QTD
-6.09%
Financial performance
How have Gilead Sciences's revenue and profit performed over time
Revenue
$28.75B
Gross profit
$22.5B
Operating income
$1.66B
Net income
$480M
Gross margin
78.3%
Net margin
1.7%
The operating income has surged by 102% since the previous quarter but it has dropped by 78% year-on-year
The operating margin has soared by 100% from the previous quarter but it has plunged by 79% YoY
Gilead Sciences's net margin has shrunk by 92% YoY
The company's net income has shrunk by 92% YoY
Growth
What is Gilead Sciences's growth rate over time
Valuation
What is Gilead Sciences stock price valuation
P/E
276.92
P/B
6.78
P/S
4.56
EV/EBIT
88.59
EV/EBITDA
33.32
EV/Sales
5.14
GILD's P/E is 102% above its 5-year quarterly average of 135.9 but 18% below its last 4 quarters average of 336.3
GILD's EPS has dropped by 92% year-on-year
The stock's price to book (P/B) is 46% more than its 5-year quarterly average of 4.6 and 25% more than its last 4 quarters average of 5.4
Gilead Sciences's equity has decreased by 15% YoY but it has increased by 4.6% from the previous quarter
GILD's price to sales (P/S) is 33% more than its 5-year quarterly average of 3.4 and 29% more than its last 4 quarters average of 3.5
GILD's revenue is up by 6% year-on-year
Efficiency
How efficient is Gilead Sciences business performance
GILD's return on assets has dropped by 90% year-on-year
The company's return on equity has shrunk by 90% YoY
GILD's return on sales has dropped by 80% year-on-year but it is up by 41% since the previous quarter
Gilead Sciences's ROIC has plunged by 78% YoY but it has increased by 42% from the previous quarter
Dividends
What is GILD's dividend history
DPS
$3.1
Dividend yield
2.95%
Payout ratio
815.8%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Gilead Sciences financials performed over time
GILD's total assets is 48% higher than its total liabilities
The quick ratio has grown by 46% from the previous quarter and by 13% YoY
Gilead Sciences's current ratio has increased by 27% QoQ and by 12% YoY
Gilead Sciences's debt is 38% higher than its equity
The company's debt to equity rose by 27% YoY and by 10% QoQ
Gilead Sciences's debt has increased by 15% QoQ and by 7% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.